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A randomised controlled trial that remained unpublished for 20 years casts doubt on the survival
benefit of further surgery after curative resection of colorectal cancer. Tom Treasure and colleagues
tell the story of the first trial restored under the restoring invisible and abandoned trials initiative and
discuss what it means today
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Old, unpublished clinical trials ordinarily remain unpublished,
their results unable to add to the scientific knowledge base, their
implications unable to affect practice. But the new restoring
invisible and abandoned trials (RIAT) initiative offers a way
forward. The RIAT concept allows third parties to publish
previously unpublished trials when the original trialists or
sponsors fail to do so.1 Last June, the editors of BMJ and PLoS
Medicine called on “researchers and editors to help restore
invisible and abandoned trials” by taking unpublished study
results and submitting them for publication.2 We were among
the first to register our intent to RIAT3 and have now published
a two decade old trial that examined the use of carcinoembryonic
antigen (CEA) to prompt “second look” surgery in colorectal
cancer.4
Role of CEA and second look surgery
In modern management, a newly diagnosed colorectal cancer
is staged, graded, and discussed by a team of surgeons,
oncologists, and radiologists with a view to curative surgery if
possible. About 16% of patients operated onwill have recurrence
of cancer within five years.5Monitoring with the tumour marker
CEA is recommended to identify these people as early as
possible. The UK’s National Institute of Health and Care
Excellence recommends CEA tests at least every six months in
the first three years plus a minimum of two computed
tomograms of the chest, abdomen, and pelvis.6 If CEA level is
raised and metastases are detected in the liver or lungs, patients
are assessed for surgery to remove the metastases with intent
to cure.
Before tumour markers were available, there was a drive to
monitor for recurrence by “second look” surgery. Second look
surgery originated in the 1950s and was promoted in the 1970s.
Asymptomatic patients at high risk of recurrence, such as those
who had had affected lymph nodes, were reoperated on at six
monthly intervals, with recurrences resected when found. If
cancer was found patients were scheduled for further operations
(up to a total of six) until the abdomen remained free of cancer.7
This approach to management was not without its critics.
Colorectal surgeonWilliam Slack wrote in 1982 that this blanket
policy might produce some cures but entailed high rates of
negative laparotomy and an unacceptable operative mortality
rate.8 Nevertheless, an analysis of 15 years’ experience of
following up patients at his hospital9 concluded that active
cancer had to be detected earlier than was possible clinically if
repeat surgery was to benefit patients. This formed the basis for
the CEA second look trial for colorectal cancer, which Slack
headed.
By the late 1970s it had been established that raised CEA levels
detected cancer recurrence on average four months before it
was clinically evident10 and had a low false positive rate.11 12
Testing could spare patients without raised CEA levels needless
second look surgery, and early detection was expected to lead
to a better prospect of resecting all recurrent disease than when
clinical criteria were used to prompt reoperation. It was not
clear, however, whether this would result in better survival,
which prompted an National Institutes for Health consensus
statement calling for trials into CEA with second look surgery
in 1981.13 Slack and colleagues incorporated CEA testing into
a study of second look surgery. The design, by identifying
patients with active cancer at the earliest possible point, gave
surgery the best chance of being effective.
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What the trial did
The Carcinoembryonic Antigen Second Look Trial set out to
enrol 2000 participants who had had curative resection of
colorectal cancer, 500 of whom were expected to have a rise in
CEA level indicative of recurrence on regular monitoring. Half
of those with a CEA rise were randomised to immediate second
look surgery and half to continued routine clinical care, which
at the time was clinical review every three months for the first
year, then six monthly until there was clinical suspicion of
recurrence. At this point second look surgery was also to be
considered. The hypothesis was that CEA monitoring would
increase the success rate of second look procedures, in terms of
macroscopic clearance, from 25% to 55%. The trial was powered
to detect a resulting improvement in survival from 10% to 22%
at five years.8 4According to the protocol surgeons were to resect
any recurrence at the surgical site, in the peritoneum, or in lymph
nodes. They were also to mobilise the liver to identify and resect
metastases.
The trial started in 1982 and by 1993 had recruited 1447 of the
intended 2000 participants and randomised 216 when it was
stopped early. The data monitoring committee thought that it
was highly unlikely that any survival advantage would ever be
shown.14 15 When the trial was unblinded it was found that there
were more deaths in the active arm than the control arm (91 v
88; relative risk=1.16, 95% confidence interval 0.87 to 1.37).4
This important finding might have influenced practice, but it
remained unpublished for 20 years.
How the trial was lost
The study ran for longer than expected and was affected by
various organisational changes. Recruitment was slow, and only
15% of patients met the stringent criteria for randomisation
rather than the 25% predicted. During the course of recruitment,
the trial unit moved from King’s College Hospital, London, to
University College London. Slack, the chief investigator, retired
and John Northover, who had been a driving force throughout,
took on that role.
Although the study was stopped early, there was a clear intention
to publish. The primary outcome, survival, was recorded in an
abandoned version of the manuscript dated 6 July 1994 that we
found in the archive and had been revealed publicly in a letter
to JAMA14 and in a conference abstract in the British Journal
of Cancer.15 The methods and results appear complete in the
manuscript prepared for submission in 1994 but the discussion
halts after three lines with a comment about the identification
and analysis of subsets. Our interpretation is that differences
over attempts to perform post hoc exploratory analyses may
have led to the breakdown of the efforts to publish in 1994.
The data then languished until after the sudden death of the trial
statistician, Kenneth MacRae, in April 2002. The study was
referred to two trial statisticians outside the trial centre, who
looked at the electronic files around 2003. They failed to access
the data to their satisfaction, deeming them “corrupted,” and a
decision was made to not reopen the analysis.
Piecing the trial back together
In the face of increasing referrals for pulmonarymetastasectomy
in colorectal trials a proposal was made for a trial in 200916
comparing active monitoring with active monitoring plus
pulmonary metastasectomy in patients who had curative
resection for colorectal cancer, the Pulmonary Metastasectomy
in Colorectal Cancer (PulMiCC) trial.17 The trial was designed
to resolve the paradox that patients who had pulmonary
metastases detected by CEA were being referred for
metastasectomy despite consistent reports that raised CEA levels
were associated with poor survival after pulmonary
metastasectomy.18 19 As the data from the second look study
were relevant to PulMiCC, in August 2009 we asked Northover
what had happened to the results. He believed the data to be
irretrievably lost. Michael Baum, who headed the trial’s data
monitoring committee, thought the same. In October 2009 we
contacted others involved at the time. The UCL clinical trials
centre response was that the data were corrupted.
One of us, KM, had recently left UCL and was aware of the
trial’s history and electronic database problems but she knew
that the files were still in the unit (fig 1⇓). On 6 November 2009
TT asked the current director of the trial centre, Jonathan
Ledermann, for access to the data. We were eventually given
access in March 2011. Staff at the trial centre retrieved the
archived electronic files and the centre’s director authorised our
access to an anonymised copy, saying, “The problem is that the
data are in a total mess.”
We discovered that the data were not corrupted but difficult to
analyse. The 1980s had been a time of rapid development in
computing and software, demanding steep learning curves in
its implementation. File transfers by temporary staff and various
informal codes inserted into the data had made data extraction
seem impossible at first sight, but we were able to restore
trustworthy and usable records for 1446 of the 1447 participants.
We then updated the survival data to September 2011. The data
available in February 1993 were that 91/108 patients had died
in the “aggressive” arm and 88/108 in the “conventional” arm
(relative risk=1.16, 95% confidence interval 0.87 to 1.37). Our
updated analysis confirms that there is no hint of a survival
advantage associated with knowledge of the CEA (fig 2⇓).4
We spoke to as many as we could find of those listed in the trial
documents at the outset8 and in the draft manuscript to check
we hadmade sense of the data and had not overlooked anything.
It was clear that the trial team had broken up in disarray, but
those we spoke to regretted that the trial had not been published
and supported us now doing so.
What the trial means today
By the time that the CEA trial closed clinical practice had
shifted. CEA testing had become commonplace after curative
resection of colorectal cancer, and liver and lungmetastasectomy
had been adopted based on observational evidence (box).20 21 In
1992 the Mayo Clinic proposed that a randomised trial should
be done to determine the survival difference resulting from
resection of liver metastases compared with no resection.22 It
proposed that if the difference in five year survival with liver
metastasectomy was 25% versus 1%, as was being claimed,
only 36 randomised patients would be needed to confirm an
effect. However, the trial did not take place because of a general
view that “it would be difficult to obtain informed consent from
patients randomised to no treatment despite resectable disease
and, in view of reported results of surgical resection, it is
unlikely that ethical committees would agree to such a trial.”35
Although the CEA second look trial found no benefit from an
overall policy of detecting and resecting disseminated cancer,
organ specific resection of metastases has become common
practice. The recent Follow-upAfter Colorectal Surgery (FACS)
trial5 tested the effectiveness of intensive monitoring with CEA
testing, computed tomography, or both compared with no
scheduled follow-up except a single computed tomogram of the
chest, abdomen, and pelvis at 12 to 18 months if requested at
study entry by the hospital clinician.5 There was a higher death
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How the CEA Second Look Trial was left behind by events
1954:Wangensteen advocated second look surgery in asymptomatic patients after colorectal cancer7
1971-78: Resection of recurrent cancer after potentially curative resection of colorectal cancer was believed to sometimes lead to “cure”23-25
1974-80: CEA was shown to detect asymptomatic recurrence of colorectal cancer10 26-29
1981: National Institutes for Health consensus called for a trial of CEA30
1982: Slack and Northover started the CEA Second Look trial8
1982-89: Hughes published an international registry of hepatic metastases resection from 24 institutions in North America, England, and Germany. After
excluding 30 day mortality, they reported five year survival of 30%31-34
1990-91: Surgeons at Erlangen University Hospital, Germany, publish their results for liver resections. After exclusion of 5.5% postoperative death five
year survival was 39%35-37
1992: Memorial Sloan-Kettering Cancer Center in New York published 10 year results of pulmonary metastasectomy in colorectal cancer. Five and 10
year survival rates were 40% and 30%, respectively38
1992: Mayo Clinic surgeons publish the power calculation for a randomised trial of liver resection suggesting that 36 patients would have been sufficient
to prove benefit39
1994: CEA Second Look Trial results available14 15
1994: Erlangen group wrote in the Lancet, “The benefit in outcome provided by resection of colorectal liver metastases had been clearly demonstrated’
based on 30% five-year disease-free survival amongst the 10-20% of their patients selected for this surgery”40
1994: Erlangen group wrote “trials on … effectiveness of hepatic resection for metastatic colorectal cancer [would be] not only obsolete but unethical”41
rate in the intensivemonitoring group (18.2% (164/901) v 15.9%
(48/301); difference 2.3%, 95% CI −2.6% to 7.1%). The study
had originally intended to estimate the difference in overall
survival but “in 2007 when it became clear that we could not
recruit the number of participants necessary to estimate an effect
on overall survival with adequate statistical power” the primary
outcome was changed to “surgical treatment with curative
intent.” This was not, in fact, “curative” surgery since it is not
associated with higher survival rates. The FACS trial results
are in accordance with the absence of survival benefit found in
the CEA second look trial in 1994.
Methods of detection, imaging, and surgical resection have
changed over the intervening 20 years and those committed to
resecting metastases may well regard the results of the restored
CEA Second Look trial as irrelevant. We take a different view.
We do not believe that the findings of the CEA trial can be
readily discounted but rather consider that the onus is on those
promoting unproved operations to test their effectiveness in
controlled trials.
Contrary to a commonly held view among surgeons, patients
are not the obstacle to trials. In the National Cancer Patient
Experience Survey of over 70 000 patients in the British
National Health Service around two thirds did not have cancer
research discussed with them, though half would have preferred
that it had been.42 Of the patients who were made aware of
research, two thirds went on to be included in research studies.
Patients are entitled to a voice, but are we listening?
We believe that the new evidence should fuel uncertainty about
present day second look surgery for colorectal cancer in its
various forms and hope that it will give some encouragement
to undertake the randomised trials that are needed. Within the
NHS these studies could be promoted by the National Institute
for Health Research and the National Cancer Research Institute.
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Fig 1 Rediscovered data files for the CEA second look study
Fig 2 Kaplan-Meier analysis of survival among participants in the Carcinoembryonic Antigen (CEA) Second Look Trial4
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